Gastrointestinal Cancer | Specialty

Treatment Options for Advanced CRC

August 8th 2014

New Tactics Needed: Aspirin Studies in Colon Cancer Illustrate Shortcomings of Phase III Trial Orthodoxy

August 5th 2014

There is a tension in the air these days when it comes to the manner in which evidence-based oncology research should be conducted in this revolutionary era, and that tension is evident on the pages of peer-reviewed articles describing novel findings in clinical molecular oncology, in editorials discussing these studies, and in commentaries related to future approaches to discovery.

Dr. Wang-Gillam Discusses the Mechanism of Action of MM-398

August 4th 2014

Andrea Wang-Gillam, MD, PhD, assistant professor, Department of Medicine, Oncology Division, Washington University School of Medicine in St. Louis, discusses the mechanism of action of MM-398, a novel encapsulation of irinotecan in a long-circulating nanoliposome.

Dr. Thomas Discusses the Potential Utility for PF-03446962 in HCC

July 25th 2014

Melanie B. Thomas, MD, medical oncologist, associate director for clinical trials, Hollings Cancer Center, Medical University of South Carolina, discusses the potential utility for the monoclonal antibody PF-03446962 in hepatocellular carcinoma (HCC).

Dr. Bekaii-Saab Discusses an Analysis of Bevacizumab or Cetuximab for CRC

July 24th 2014

Tanios Bekaii-Saab, MD, discusses an analysis of two targeted drugs for the treatment of patients with colorectal cancer (CRC).

Final Thoughts on Optimizing the Treatment of mCRC

July 23rd 2014

TAS-102 in Refractory mCRC

July 23rd 2014

Optimizing Treatment With Regorafenib in mCRC

July 23rd 2014

BRAF-Mutated Colorectal Cancer

July 23rd 2014

Second-Line Treatment Options in mCRC

July 23rd 2014

Future Analyses From the 80405 mCRC Trial

July 23rd 2014

Conducting Extended RAS Testing in CRC

July 23rd 2014

Extended RAS Testing in Metastatic CRC

July 23rd 2014

CALGB 80405 Trial Results in mCRC

July 23rd 2014

Introduction: Bevacizumab Versus Cetuximab in mCRC

July 23rd 2014

Dr. Hoff on Delivering Chemotherapy Until Progression Versus Complete Stop in mCRC

July 22nd 2014

Paulo Marcelo Hoff, MD, PhD, FACP, University of São Paulo, Brazil, discusses a meta-analysis of randomized trials that examined the effect of chemotherapy delivered until progression versus complete stop on the overall survival of patients with metastatic colorectal cancer (mCRC).

Immunotherapy Combination Receives Breakthrough Designation for Pancreatic Cancer

July 21st 2014

The combination of the immunotherapy CRS-207 and the vaccine GVAX Pancreas has received a breakthrough therapy designation from the FDA for its potential as a treatment for patients with metastatic pancreatic cancer.

Dr. Abou-Alfa Discusses the STORM Trial in HCC

July 17th 2014

Ghassan K. Abou-Alfa, MD, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the findings from the STORM trial, a phase III randomized, double-blind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma (HCC).

Dr. Ilson Discusses the Findings of the RTOG 0436 Trial

July 8th 2014

David H. Ilson, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the conclusions of the RTOG 0436 trial, a phase III trial of cisplatin, paclitaxel, and radiation with or without cetuximab in the non-operative treatment of esophageal cancer.

Dr. Fakih on Advances in Liver-Directed Therapies in CRC

July 3rd 2014

Marwan G. Fakih, MD, professor, director, Gastrointestinal Medical Oncology, City of Hope, discusses recent advances in liver-directed therapies in colorectal cancer (CRC).